Logotype for Bayer AG

Bayer (BAYN) investor relations material

Bayer Investor update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Bayer AG
Investor update summary2 Sep, 2026

Strategic framework and financial targets

  • Five-Year Framework targets €3.5 billion in top-line growth, mid-20s EBITDA margin, and €1.5 billion cumulative cash generation by 2029, driven by innovation and operational efficiency.

  • Margin improvements of over €1 billion are targeted, with €380 million already delivered, mainly from product supply and sourcing initiatives.

  • Cash productivity is ahead of schedule, with €500 million inventory reduction in 2025 and a goal of over €3 billion free operating cash flow by 2029.

  • Net sales are expected to grow at a 3% CAGR through 2029, outpacing the ~2% market growth, with corn and other seeds & traits as main growth drivers.

  • Licensing revenues remain robust, with over €2 billion net annually expected until 2030, underpinned by technology leadership and multi-decade agreements.

Operational execution and cost transformation

  • Product supply improvements focus on sourcing, network optimization, and seed production, targeting €600 million in EBITDA impact by 2029.

  • Nearly €400 million in cost reductions and €500 million in inventory reductions have been achieved, with further portfolio pruning and R&D restructuring underway.

  • Active ingredient production is being shifted from Europe to more cost-competitive regions, mainly China and India, to address global overcapacity and energy price pressures.

  • Go-to-market and SG&A cost reductions are being achieved through country archetype segmentation, digitalization, and functional productivity programs.

  • Working capital productivity is being enhanced through inventory, payables, and receivables management, supporting cash flow targets.

Innovation pipeline and growth drivers

  • Commercialization of two blockbuster products has begun, with more launches planned, targeting at least 10 blockbusters in a decade, each with peak sales potential of €500 million or more.

  • Corn is the main growth engine, with double-digit growth, geographic expansion, and the Preceon Smart Corn System expected to drive a 4 percentage point market share gain by 2035.

  • Soybean is stabilizing, with major growth expected post-2028 from Vyconic and Intacta 5+ launches, which are expected to exceed €3 billion in peak sales.

  • Core Crop Protection focuses on profitable growth via blockbuster launches (Plenexos, Icafolin), lifecycle management, and portfolio optimization.

  • Non-Core Crop Protection (glyphosate/Ruveon) is managed as a lean, commodity-focused business, with profitability prioritized over top-line growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Bayer earnings date

Logotype for Bayer AG
Q3 2026 (Media)3 Nov, 2026
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Bayer earnings date

Logotype for Bayer AG
Q3 2026 (Media)3 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Bayer AG operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The company researches, develops, manufactures, and markets prescription products primarily for the areas of cardiology and women's healthcare; and specialty therapeutics in the areas of oncology, hematology, and ophthalmology. It is also involved in developing over-the-counter medications and dietary supplements.